Rexford Capital Inc. Buys Shares of 6,279 Gilead Sciences, Inc. $GILD

Rexford Capital Inc. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,279 shares of the biopharmaceutical company’s stock, valued at approximately $696,000.

Other institutional investors and hedge funds have also modified their holdings of the company. GoalVest Advisory LLC grew its holdings in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Activest Wealth Management boosted its position in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences in the 2nd quarter worth $27,000. Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences during the second quarter worth $30,000. Finally, Putney Financial Group LLC increased its holdings in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Scotiabank assumed coverage on Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price on the stock. Rothschild & Co Redburn lifted their price objective on shares of Gilead Sciences from $143.00 to $153.00 in a research note on Monday, November 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research note on Friday, October 31st. Argus increased their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, TD Cowen boosted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $131.13.

Insider Buying and Selling

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the sale, the insider owned 107,193 shares in the company, valued at $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 135,757 shares of company stock valued at $16,616,127. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $120.40 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The firm’s 50 day moving average price is $121.89 and its two-hundred day moving average price is $115.76. The firm has a market cap of $149.38 billion, a P/E ratio of 18.67, a PEG ratio of 0.67 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the prior year, the firm earned $2.02 earnings per share. The firm’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.